Your Meds Aren't Working. Your Genes May Be Metabolizing Them Too Fast.

CYP2D6 encodes an enzyme responsible for metabolizing approximately 25% of all prescription medications. It breaks down antidepressants like sertraline and paroxetine, opioid pain relievers like codeine and tramadol, beta-blockers like metoprolol, and antipsychotics. This single enzyme is one of the most important drug-processing workhorses in your liver.

The CYP2D6 gene is notorious for its variants. Some people carry *2, *4, *10, or *17 variants that reduce enzyme activity. But others carry gene duplications, meaning they have extra copies of the gene. Ultra-rapid metabolizers with duplications may have two, three, or even more functional copies, causing them to metabolize drugs at two to four times the normal rate. This is especially problematic for opioids and antidepressants, where consistent blood levels are essential for therapeutic effect.

If you’re an ultra-rapid CYP2D6 metabolizer, a standard dose of sertraline may reach therapeutic levels for only a few hours before being completely cleared. Your pain medication may wear off in half the time it’s supposed to. You may feel like you have a naturally high tolerance to these drugs, not realizing your genes are the reason.

CYP2C19 metabolizes several drug classes essential for heart health and mental health. It breaks down clopidogrel (a blood thinner used after heart attacks), many proton pump inhibitors used for acid reflux, and a range of antidepressants including escitalopram and citalopram.

Poor metabolizers with *2 or *3 variants get all the research attention because they carry toxicity risk. But ultra-rapid metabolizers, typically carrying the *17 variant, face the opposite problem. Roughly 5-15% of people depending on ancestry carry ultra-rapid CYP2C19 variants that speed up drug breakdown by 50-100%. For clopidogrel, which is a prodrug requiring metabolism to become active, ultra-rapid metabolizers don’t just fail to benefit from the drug, they may get paradoxically elevated bleeding risk at standard doses because some metabolite accumulates while the active form remains insufficient.

If you’ve had a stent placed after a heart attack and take clopidogrel, or if you’re on an antidepressant that relies on CYP2C19, being an ultra-rapid metabolizer means standard dosing leaves you unprotected or undertreated.

CYP2C9 metabolizes warfarin (a blood thinner), many NSAIDs like ibuprofen and naproxen, and some statins. Warfarin is a classic example of a drug where genetic variation matters enormously. The standard starting dose of warfarin is calculated for someone with normal CYP2C9 function, but individuals vary dramatically in how quickly they clear it.

While poor metabolizers with *2 or *3 variants are at high risk for bleeding at standard doses, ultra-rapid metabolizers face the opposite problem. Ultra-rapid CYP2C9 metabolizers may clear warfarin so quickly that standard doses never reach therapeutic anticoagulation levels, leaving them at risk for clots despite taking the medication. Roughly 5-10% of people of European ancestry carry variants affecting CYP2C9 function, though ultra-rapid metabolizers are less common than poor metabolizers.

If you take warfarin or high-dose NSAIDs and feel like standard doses aren’t working, or if you’re having trouble achieving stable anticoagulation, your CYP2C9 status may be the reason.

SLCO1B1 encodes a transporter protein that actively pumps statins from the bloodstream into liver cells, where they work to lower cholesterol. This is a critical step in statin efficacy. The gene has a common variant called *5 or rs4149056, carried by roughly 15% of people of European ancestry.

Unlike the CYP enzymes, SLCO1B1 isn’t about how fast you break down the drug. Instead, the SLCO1B1 *5 variant reduces the efficiency of statin uptake into the liver, meaning less of the drug reaches the tissue where it needs to act. People with this variant have higher systemic statin exposure, meaning statins stay in the bloodstream longer where they can cause side effects, while simultaneously being less effective at lowering cholesterol because they’re not entering the liver efficiently.

If you’ve experienced statin-induced muscle pain or elevated liver enzymes at doses that seemed reasonable, or if your cholesterol won’t budge despite taking a statin, your SLCO1B1 status may explain it. You may need a different statin class or adjusted dosing.

VKORC1 encodes vitamin K epoxide reductase, the enzyme that recycles vitamin K in your body. Warfarin works by blocking this enzyme, reducing vitamin K recycling and thinning your blood. But genetic variation in VKORC1 itself determines how much warfarin you need to block it effectively.

The most common variant is -1639G>A. People carrying the A allele, roughly 40% of European ancestry populations, have reduced baseline vitamin K recycling and are exquisitely sensitive to warfarin, requiring much lower doses than the standard protocol. This isn’t about how fast you metabolize warfarin (that’s CYP2C9’s job). This is about how much warfarin you need to achieve the same anticoagulant effect.

If you’ve been told you need an unusually low warfarin dose, or if you achieve target INR levels easily while others struggle, your VKORC1 status is likely the reason. Genetic-guided warfarin dosing has been shown to reduce bleeding and clotting events compared to standard dosing.

MTHFR encodes methylenetetrahydrofolate reductase, an enzyme that converts folate into its active form, methylfolate. This active form is used throughout your body for DNA synthesis, amino acid metabolism, and neurotransmitter production. It also affects how your body processes certain medications, particularly methotrexate, a drug used for autoimmune conditions and cancer.

The C677T variant, carried by roughly 40% of people of European ancestry, reduces MTHFR enzyme activity. People with this variant have impaired conversion of dietary folate into the active methylfolate form, affecting not only their baseline folate status but also their ability to process and respond to methotrexate and other folate-pathway drugs. This doesn’t make you an ultra-rapid metabolizer in the traditional sense, but it does affect how you respond to medications that depend on folate metabolism.

If you’re taking methotrexate for rheumatoid arthritis or another condition and feel like standard doses aren’t working, or if you develop folate deficiency despite adequate dietary intake, your MTHFR status may be relevant. You may benefit from supplemental methylfolate or adjusted dosing protocols.